NFKB1 and systemic lupus erythematosus: Since the INH-ODNs tested here suppressed IFN-α-release by human and murine cells (Fig. 3, 4) and impaired activation of NF-κB [22], treatment of SLE patients with INH-ODNs could potentially replace therapy with corticosteroids in patients not responding to the latter.